-
The Centers for Disease Control and Prevention (CDC) has a free webinar of its recent Public Health Grand Rounds, "The Growing Threat of Multidrug-Resistant Gonorrhea, available on its web site.
-
Review the records of the girls who have received at least one injection in the three-series vaccination series for human papillomavirus (HPV). How many have completed the series? If new research is any indication, the proportion of those receiving all three shots is low.
-
Family planners now have proof positive that the intrauterine device (IUD) and the contraceptive implant, two long-acting reversible contraceptives (LARC methods), are superior in their effectiveness, compared to the effectiveness of the contraceptive pill, patch, or ring.
-
A report from the Guttmacher Institute reveals the U.S. teen pregnancy rate is at its lowest level in 40 years and the teen birth rate is at the lowest point since consistent data was collected in the 1950s.
-
A study of cervical cancer incidence and mortality in North Carolina has revealed areas where rates are unusually high, prompting public health officials to call for education, screening, and vaccination programs in impacted areas.
-
According to a new economic analysis of the DC Female Condom program, a public-private partnership to provide and promote FC2 Female Condoms (Female Health Co., Chicago), the program prevented enough HIV infections in the first year alone to save more than $8 million in future medical care costs over and above the cost of the program.
-
Get ready to add two sets of guidance on cervical cancer screening to your practice database: the most current recommendations from the U.S. Preventive Services Task Force (USPSTF) and joint cervical cancer prevention guidelines issued by the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology (ACS/ASCCP/ASCP).
-
How many chlamydia tests were performed on sexually active women ages 15-25 in your clinic last year? If your numbers are similar to a new national analysis, about 38% of sexually active young women ages 15-25 were screened for the sexually transmitted disease (STD).
-
About three million U.S. women experience heavy menstrual bleeding each year.1 With the recent Food and Drug Administration (FDA) approval of Natazia (Bayer HealthCare Pharmaceuticals, Wayne, NJ) for treatment in women who choose an oral contraceptive (OC), clinicians now have another therapeutic option.
-
Ulipristal acetate, the drug recently approved as an emergency contraceptive in the United States (Ella, Watson Pharmaceuticals, Morristown, NJ), is being eyed for other gynecologic uses. In research looking at women with symptomatic fibroids who were planning to undergo surgery, treatment with the selective progesterone-receptor modulator was effective in controlling excessive bleeding and reducing fibroid size at 13 weeks.
